The potential anti-HBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in HepG2 2.2.15 cells
Authors:
- 1 April 2005
- journal article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 28 (4) , 451-457
Abstract
Experimental studies have demonstrated that the triple combination of amantadine (A)/ ursodeoxycholic acid (UDCA, U)/ biphenyl dimethyl dicarboxylate (DDB, D) might have a preferential antiviral effect compared with that observed in interferon-induced antiviral signal pathways, such as those of STATIα and the 6-16 genes. To confirm the results, this study examined whether the signal transduction for the antiviral activity in HepG2 2.2.15 was induced dependently or independently of interferon. To accomplish this, the correlation between the STATIα and 6-16 genes, and nitric oxide, for the mediation of the antiviral activity was assessed. The increase in nitric oxide in the UDCA groups suggests that the inhibition of viral gene replication was enhanced by the amantadine combinations (AU and AUD), and might be more effective if incubated for longer periods. It was found that STATIα was activated by the amantadine combination, although to a lesser extent than that of interferon-α, and the primary endpoints examined for the inhibition of gene expression (HBsAg and HBcAg) were remarkably well regulated. This suggests that the amantadine triple, or at least the double, combination had better clinical benefits than those of IFN-α and the nucleoside analogue single treatment. This demonstrates that the amantadine combination might be a substitute for the existing HBV therapy if the results ofin vivo and in vitro studies concur.Keywords
This publication has 27 references indexed in Scilit:
- Treatments for Hepatitis BClinical Infectious Diseases, 2004
- Antivirals and antiviral strategiesNature Reviews Microbiology, 2004
- Temporal activation of NF-κB regulates an interferon-independent innate antiviral response against cytoplasmic RNA virusesProceedings of the National Academy of Sciences, 2003
- Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patientsHepatology, 2000
- Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot studyAlimentary Pharmacology & Therapeutics, 1999
- Treatment of Chronic Hepatitis C With Interferon With or Without Ursodeoxycholic AcidJournal of Clinical Gastroenterology, 1998
- Therapy of hepatitis C: Other optionsHepatology, 1997
- Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling ProteinsScience, 1994
- Nitric Oxide: A Physiologic MessengerAnnals of Internal Medicine, 1994
- Hepatitis B virus.The major etiology of hepatocellular carcinomaCancer, 1988